Medical Cannabis — page 2

Spasticity is one of the most disabling symptoms of MS and spinal cord injury. Here is what the science says about cannabis, nabiximols, and relief.

What the THC trials and the CANNA-TICS nabiximols study actually show about cannabis for Tourette's tics, plus observed dosing and who it may help.

Florida stays medical-only in 2026 after Amendment 3 fell short of 60%. Here's the medical program, penalties, the 2026 ballot fight, and hemp rules.

Georgia's 2026 cannabis laws explained: the medical registry, the old 5% THC cap, SB 220's overhaul, dispensaries, penalties, and the hemp gray market.

Nebraska cannabis laws in 2026: voters approved medical marijuana in 2024, but a contested rollout means patients still wait. Here is where it stands.

NJ cannabis laws in 2026: possession and purchase limits, why home grow is banned, where to buy, public use, DUI, jobs, and expungement explained.

New York cannabis laws in 2026: possession limits, home grow, the rocky retail rollout, public use, social equity, and NYC taxes explained plainly.

Pennsylvania cannabis in 2026: medical-only, 24 qualifying conditions, no home grow, a decrim patchwork, and a stalled adult-use push explained.

South Dakota cannabis laws in 2026: medical only after voters' recreational wins were struck down or rejected. Cards, conditions, possession, penalties.

Texas cannabis laws in 2026: no recreational, a low-THC medical program, a booming hemp-THC market, criminal possession penalties, and the ban fight.

Cannabidivarin (CBDV) is a non-intoxicating cannabinoid studied for epilepsy and autism. Here's the honest science, including the trials that fell short.

A clear, step-by-step guide to getting a medical marijuana card in 2026 — qualifying conditions, telehealth evals, state fees, and why a card still pays off.

Cannabis is decriminalized in Portugal, not legal. 25 years on from the 2001 reform: the 25g limit, medical access, and what tourists need to know.

RSO and FECO are both thick full-spectrum cannabis oils, but solvent, testing, and labeling set them apart. Here is how to tell them apart and choose.

A 2026 study found CBC and CBG with silver nanoparticles killed MRSA 64x more effectively than silver alone — with zero resistance development. The science.

A 2026 cohort of 300,000+ patients found cannabis use disorder linked to 3.87x higher lung cancer risk. The data, the caveats, and what it means for users.

A 2026 scoping review of 28 RCTs across 12 DSM-5 conditions. Where cannabinoids show benefit, where evidence is thin, and what we still don't know.

Depressed patients widely use cannabis for sleep — and the science is nuanced. Real perceived benefit, real architecture concerns. What 2026 research shows.

A 2026 longitudinal study of 11,000+ youth shows THC exposure tracks with measurable brain trajectory changes — while CBD does not. The data parents need.

The first randomized trial of cannabis for acute migraine: vaporized THC+CBD flower beat placebo for pain freedom at 2 hours. What the science actually says.

Cannabis flavonoids — especially cannflavin A — match ibuprofen for anti-inflammatory potency. The third bioactive category most consumers have never heard of.

The UK Medical Cannabis Registry tracked 698 patients prescribed cannabis for depression. Mood, sleep, and anxiety all improved — with one important caveat.

Cannabis terpenes relieve pain via adenosine A2A receptors, not CB1/CB2 — with morphine-comparable analgesia. Why this rewrites the pain conversation.

A 2026 study: cannabis works better for chronic pain when it ALSO improves sleep, stress, and mood. Why multi-system effects matter — and how to use them.